1. Jameson RM. Tissue concentrations of nalidixic acid in chronic pyelonephritis. BrMedj. 1965;2:621-622.
2.
2. Stamey TA, Bragonje J. Resistance to nalidixic acid. JAAMIA. 1976;236:1857-1860.
3.
3. Hooper DC, Wolfsen JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985;28:716-721.
4.
4. Gough A, Barsoum NJ, Mitchell L, et al. Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol. 1979;51:177-187.
5.
5. Burkhardt JE, Hill MA, Carlton WW, Kesterson JW. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol. 1990;27:162-170.
6.
6. Scully BE, Nakatomi M, Ores C, et al. Ciprofloxacin therapy in cystic fibrosis. AmJMed. 1987;82(Suppl 4A):196-201.
7.
7. Kuhn R, KangaJ, Palmejar A, Rubio T. Retrospective review of ciprofloxacin for the treatment of acute pulmonary exacerbations in pediatric CF patients. Pediatr Pulmonol. 1990; (Suppl 5):246-246(Abstract 212).
8.
8. Black A, Redmond AOB, Steen HJ, Oborska IT. Tolerance and safety of ciprofloxacin in pediatric patients. J Antimicrob Chemother. 1990;26(Suppl F):25-29.
9.
9. Rubio TT. Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis. Diagn Microbiol Infect Dis. 1990;13:153-155.
10.
10. Schaad UB, Wedgewood-Krucko J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection. 1987;15:165-168.
11.
11. Chysky V, Kapila K, Hullmann R, et al. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use: emphasis on joint evaluation. Infection. 1991;19:289-296.
12.
12. Schaad UB, Stoupis C, WedgwoodJ, et al. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J. 1991;10:723-729.
13.
13. Schaad UB, Sander E, Wedgwood J, Schaffner T. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. Pediatr Infect DisJ1992;11:1047-1049.
14.
14. Van Wijk JAE, de Jong TPVM, Van Gool JD, et al. Using quinolones in urinary tract infections in children. Adv Antimicrob Antineopl Chemother. 1992;11(Suppl 2):157-161.
15.
15. Lang R, Goshen S, Raas-Rothschild A, et al. Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: preliminary experience in 21 children. Pediatr Infect Dis J1992;11:925-929.
16.
16. Gendrel D, RaymondJ, Legall MA, et al. Use of pefloxacin after failure of initial antibiotic treatment in children with severe salmonellosis. EurJ Clin MicrobiolInfectDis. 1993;12:209-241.
17.
17. Lolekha S, Vibulbandhitkit S, Poonyarit P. Response to antimicrobial therapy for shigellosis in Thailand. Rev Infect Dis. 1991;13 (Suppl 4):S342-S346.
18.
18. Cheesbrough JS, Mwema Fl, Green SDR. Quinolones in children with invasive salmonellosis. Lancet. 1991;338:127-127.
19.
19. Goepp JG, Lee CKK, Anderson T, et al. Use of ciprofloxacin in an infant with ventriculitis. J Pediatr. 1992;121:303-305.
20.
20. Isaacs D, Slack MPE, Wilkinson AR, Westwood AW. Successful treatment of Pseudomonas ventriculitis with ciprofloxacin. J Antimicrob Chemother. 1986;17:535-538.
21.
21. Green SDR, Ilunga SM, Cheesbrough JS, et al. The treatment of neonatal meningitis due to gram-negative bacilli with ciprofloxacin: evidence of satisfactory penetration into the cerebrospinal fluid. J Infect. 1993;26:253-256.
22.
22. Wessalowki R, Thomas L, KivitJ, Voit T. Multiple brain abscesses caused by Salmonella enteritidis in a neonate: successful treatment with ciprofloxacin. PediatrInfectDisj1993;12:683-688.
23.
23. Lumbiganon P, Pengsaa K, Sookpranec T. Ciprofloxacin in neonates and its possible effects on the teeth. Pediatr Infect Disj1991;10:619-620.
24.
24. Bannon MJ, Stutchfield PR, Weindling AM, Damjanovic V. Ciprofloxacin in neonatal Enterobacter cloacae septicemia. Arch Dis Child. 1989;64:1388-1389.
25.
25. Ragunathan PL, Potkins DS, Watson JG, et al. Neonatal meningitis due to Salmonella typhimurium treated with ciprofloxacin. J Antimicrob Chemother. 1990;26:727-728.
26.
26. Huber-Spitzy V, Steinkogler FJ, Huber E, Schiffbanker M. Norfloxacin in the treatment of congenital dacryocystitis. Orbit. 1991;10:37-40.
27.
27. Leibowitz HM, Limberg MB, Steinert RF, et al. The role of ciprofloxacin in the antibacterial therapy of bacterial keratitis and bacterial conjunctivitis. AmJOphthalmol. 1991;112:2S-14S.
28.
28. Schaefer HG, Stass H, WedgwoodJ, et al. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Antimicrob Agents Chemother. 1996;40:29-34.
29.
29. Rubio TT, Miles MV, Church DA, et al. Pharmacokinetics studies of ciprofloxacin in children with cystic fibrosis. Pediatr Res. 1994; Abstract.
30.
30. Peltola H, Vaarala M, Renkonen OV, Neuvonen PJ. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. Antimicrob Agents Chemother. 1992;36:1086-1090.
31.
31. Miller MS, Gaido F, Rourk MH, Spock A. Anaphylactoid reactions to ciprofloxacin in cystic fibrosis patients. Pediatr Infect Disj. 1991;10:164-165.
32.
32. Kresken M, Wiedemann B. Development of resistance to nalidixic acid and the fluoroquinolones after introduction of norfloxacin and ofloxacin. Antimicrob Agents Chemother. 1988;32:1285-1288.
33.
33. Schaefler S. Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones. J Clin Microbiol. 1989;27:335-336.
34.
34. Shalit I, Berger SA, Gorea A, Frimerman H. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother. 1989;33:593-594.
35.
35. Centers for Disease Control. Decreased susceptibility of Neisseria gonorrhoeae to fluoroquinolones-Ohio and Hawaii, 1992-1994. MMWR. 1994;43:325-327.
36.
36. Schaad UB, Abdus Salam M, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an international society of chemotherapy commission. Pediatr Infect Dis J. 1995;14:1-9.
